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Background. To understand the concurrent effects of human immunodeﬁciency virus (HIV) infection, the 
immune system, and antiretroviral therapy on body composition alterations, we examined annualized composition 
changes in HIV-infected adults who were receiving stable antiretroviral therapy. 
Methods. With use of data from the Nutrition For Healthy Living Study, we performed multivariate analyses 
using longitudinal models to evaluate the relationship of CD4+ cell count, viral load, and highly active antiretroviral 
therapy (HAART) or antiretroviral therapy (ART) with changes in trunk and extremity composition for 110 men 
and 42 women who provided data relating to 194 study intervals (i.e., intervals of time between 2 assessment visits). 
Of these intervals, 165 involved HAART use (89.7% involved protease inhibitor–based regimens), and 29 did not 
involve HAART use. Patients receiving HAART or ART (who had continuous use during the interval) were compared 
with HAART- or ART-naive subjects. 
Results. The median length of intervals between visits was 12.9 months (interquartile range, 12.1–17.6 months). 
In models adjusted for HAART or ART use, baseline CD4+ cell count was positively associated with increased trunk 
fat (mean increase per year, 2.3% per 100 cells/mm3; 95% conﬁdence interval [CI], 0.7%–3.9%]) and, in men, with 
increased extremity fat (mean increase per year, 1.8% per 100 cells/mm3; 95% CI, 0.6%–3.0%). Increase in CD4+ cell 
count predicted increased extremity lean mass (mean increase per year, 0.6% per 100 cells/mm3; 95% CI, 0.05%– 
1.1%). Higher baseline viral load predicted fat loss (trunk fat loss per year, �5.0% per log10 copies/mL; 95% CI, 
�9.4% to �0.7%; extremity fat loss per year, �3.4% per log10 copies/mL; 95% CI, �6.1% to �0.6%), as did 
zidovudine use (trunk fat loss per year, �10.8%; 95% CI, �20.4% to �1.4%; extremity fat loss per year, �4.9%; 
95% CI, �9.8% to �0.01%). HAART use independently predicted decreased bone mineral content (extremity bone 
mineral content loss per year, �1.6%; 95% CI, �3.1% to �0.08%) but did not predict changes in fat or lean mass. 
Receipt of protease inhibitor–based HAART predicted a �1.9% decrease in extremity bone mineral content per year 
(95% CI, �3.6% to �0.2%), and zidovudine use predicted a �2.6% decrease in trunk bone mineral content per 
year (95% CI, �4.4% to �0.8%). 
Conclusions. Baseline viral load, CD4+ cell count, and change in CD4+ cell count predicted alterations in 
trunk fat, extremity fat, and lean mass. HAART use and zidovudine use were associated with bone loss, and 
zidovudine use was associated with fat loss, but HAART use was not associated with fat mass changes. 
The complex array of morphologic changes experienced the medical and scientiﬁc community. Common 
by many HIV-infected individuals continues to puzzle changes have been reported to involve fat mass (FM), 
lean mass (LM), and bone mass (BM) in a variety of 
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patterns and combinations [1, 2]. A cross-sectional, 
multicenter study (Fat Redistribution and Metabolic 
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Change in HIV Infection Study) comparing HIV-infected per­
sons with healthy control subjects using MRI and dual–energy 
x–ray absorptiometry (DEXA) suggests that central fat accu­
mulation and peripheral fat atrophy occur independently [3]. 
Body mass index and percentage of body fat have been im­
plicated in changes in FM [4]. Recent cross-sectional and lon­
gitudinal studies report that lean mass may be increased in 
persons receiving HAART [5–7], whereas other studies have 
not found such an association [8, 9]. A drug initiation study 
found that some body composition beneﬁts that occurred after 
initiating antiretroviral therapy were transient [6]. DEXA ﬁnd­
ings suggest that bone density is low in many individuals who 
are seropositive for HIV infection [10–12] and that osteopenia 
may be associated with fat mass abnormalities [13]. 
A number of difﬁculties exist in determining the cause of 
body composition changes. One concern is the best method to 
determine regional body composition. Speciﬁc medications or 
antiretroviral therapy drug classes (e.g., protease inhibitors 
[PIs], nucleoside reverse-transcriptase inhibitors [NRTIs], and 
non-NRTIs [NNRTIs]) and antiretroviral therapy combinations 
have been reported to affect body shape differently [5, 14–18], 
and antiretroviral therapy regimens may change for a variety 
of reasons. Predictors of body shape changes appear to include 
baseline CD4+ cell count and viral load, as well as change in 
CD4+ cell count and viral load [4, 6, 14, 19]. Although there 
is no perfect marker of cumulative disease severity, CD4+ cell 
count and viral RNA serve as useful surrogate markers of cur­
rent disease activity and status. Data suggest that body shape 
changes continue to occur over time [6, 14, 19]. 
To our knowledge, no published cohort studies have reported 
the concurrent effects of medications, HIV disease markers, 
and other cofactors on measures of regional FM, LM, and BM. 
We longitudinally analyzed a medication-stable cohort of men 
and women for independent predictors of regional body com­
position alterations by DEXA. 
SUBJECTS AND METHODS 
Patients were participants in Nutrition for Healthy Living, an 
observational cohort study initiated in 1995 to describe the 
natural history of HIV disease and progression and to deter­
mine the role of nutrition. Subjects �18 years old and with all 
stages of disease were eligible. Recruitment was through ad­
vertisements in local newspapers, radio, health clinics, and phy­
sician networks in Boston, Massachusetts, and Providence, 
Rhode Island. Exclusion criteria included pregnancy, severe di­
arrhea, diabetes, thyroid disease, malignancies other than Ka­
posi sarcoma, or poor English language ﬂuency at the time of 
recruitment. Subjects made study visits at ∼6-month intervals 
and completed surveys and 3-day food records and had blood 
samples drawn at each visit. Since 1997, annual DEXA scans 
have been conducted. Enrolled subjects continue to receive care 
from their treating physicians. Additional details of the study 
have been published elsewhere [8]. 
All subjects with a minimum of 2 DEXA scans conducted 
at visits 11–24 months apart between June 1997 and June 2001 
who had complete medication information were included in 
this analysis (ﬁgure 1). For a subject to be included, medication 
status had to be continuous 1 month prior to and throughout 
the entire interval. If participants were involved in intervention 
studies affecting nutrition or body composition, data for these 
intervals and the 6 months after intervention were excluded. 
Although 291 Nutrition for Healthy Living participants met 
the 2-DEXA minimum in this time frame, only 110 men and 
42 women met inclusion criteria for this analysis. Data available 
on single individuals over multiple visits were used to create 
multiple intervals for some of the subjects. These 152 individ­
uals provided data for 194 intervals. Table 1 reports baseline 
values for subject characteristics. Table 2 reports the body com­
position characteristics at the start of each interval used in this 
analysis. HAART users, deﬁned as those reporting continuous 
use of HAART throughout the interval, were compared with 
participants who were deemed to be HAART naive on the basis 
of our data collection. Similarly, for speciﬁc medications and 
medication classes, continuous users of each medication or 
medication class were compared with those with no prior or 
current use of the speciﬁed medication or medication class 
reported. Duration of HAART or of antiretroviral therapy was 
deﬁned as the number of months of previous cumulative use, 
as determined by self-report at study entry, plus the months 
to the start of an interval. 
Figure 1. Subject and interval selection. ART, antiretroviral therapy; 
DEXA, dual-energy x-ray absorptiometry. 
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Testing protocol. The protocol was approved by the Tufts 
University Human Investigation Review Committee. Written 
informed consent was obtained from all participants. 
Transverse whole-body DEXA scans were obtained with a 
single QDR2000 scanner (Hologic) in the array mode, per­
formed by 1 of 3 validated technicians, and followed the pre­
scribed Nutrition for Healthy Living protocol [5]. Whole-body 
and regional analyses of soft tissues were performed using the 
QDR2000 product software, version 7.10A (Hologic). 
Individual antiretroviral medication use and duration of use 
were recorded at each visit. Individual antiretroviral drugs were 
classiﬁed by drug class (i.e., PI, NRTI, or NNRTI) and by drug 
combinations as HAART or non-HAART. HAART regimens 
included (1) �2 PIs (PI-based HAART), (2) �1 PI and �2 
NRTIs (PI-based HAART), (3) �1 PI,  �1 NRTI, and �1 
NNRTI (mixed HAART), (4) �2 NRTIs and �1 NNRTI 
(NNRTI-based HAART), or (5) �3 NRTIs (NRTI-based 
HAART). An antiretroviral therapy user or HAART user was 
deﬁned as someone reporting continuous antiretroviral therapy 
or HAART use from the beginning of the interval through the 
end of the interval. A subject was considered to be antiretroviral 
therapy naive or HAART naive if there was no antiretroviral 
therapy or HAART use in the 12 months before entry into the 
Nutrition for Healthy Living study and none initiated by the 
date of the ﬁnal DEXA. 
History of AIDS diagnosis included a CD4+ cell count !200 
cells/mm3 at the time of any study visit, self-reported occur­
rence of any AIDS-deﬁning illness, or AIDS diagnosis before 
or during participation in the Nutrition for Healthy Living 
study. HIV RNA level was measured with the Roche Amplicor 
Monitor RT-PCR assay (Roche Molecular Systems), with a 
lower limit of detection of 400 copies/mL. Viral loads that were 
undetectable using this assay were assigned the mean value of 
200 copies/mL (i.e., 2.3 log10 copies/mL). CD4
+ lymphocyte 
counts were performed using a speciﬁc monoclonal antibody 
and ﬂuorescence-activated, cell-sorted analysis. 
Statistical analysis. Under the guidance of a research stat­
istician, statistical analyses were performed using SAS software, 
versions 8 and 9 (SAS). Subjects’ characteristics were tabulated 
on the basis of the individual’s data at the baseline of their ﬁrst 
interval, as well as from all included intervals. Binary charac­
teristics were described by CD4+ cell count and by percentage 
of nonmissing values. Differences between groups were tested 
for signiﬁcance using the x2 test or, if there were !5 observations 
in a cell, using the Fisher exact test. Continuous characteristics 
were expressed as mean (SD) or, if the data were highly 
skewed, as median (interquartile range). Differences between 
groups were tested for signiﬁcance using the Student’s t test 
or, if the data were highly skewed, the Wilcoxon rank sum test. 
All statistical tests were 2-sided, and a was set at 5%. 
The units of analysis were intervals, with an interval deﬁned 
as the time between 2 DEXA scans. To account for the variations 
in time between the actual DEXA scan dates, data were pro­
portionally adjusted to a 12-month period, and thereby created 
annualized change. The dependent variable in regression mod­
els was annualized percentage change in 6 body composition 
measures; these included FM, LM, and bone mineral content 
(BMC) in trunk and extremities (i.e., arms plus legs), as deﬁned 
by DEXA. All independent variables (i.e., HAART use, HAART 
class, antiretroviral therapy use, antiretroviral therapy class, 
baseline CD4+ cell count, baseline viral load, age, sex, strength 
training, smoking, and dietary intake) were measured at the 
beginning of the interval, with the exception of annualized 
change in CD4+ cell count and viral load, which were measured 
over the interval. The within-person correlations were modeled 
as ﬁrst-order autoregressive, to account for decreasing serial 
correlation. All models were implemented with SAS Proc Mixed 
(SAS) to allow for multiple intervals per person. All inferences 
were conducted using the empirical SE to account for within-
person correlation [20]. This allows valid statistical inferences 
to be made using data that come from 11 observation per 
person. 
Model diagnostics—including Cook’s distance, deletion of 
outliers, residual plots, and normal probability plots—were 
used to check for inﬂuential points, nonnormality, nonlinear­
ities, and unequal variances. The stepwise restricted cubic spline 
[21] was also used to check for nonlinearities. 
Multivariate, longitudinal models separately assessing the ef­
fect of CD4+ cell count and viral load on change in FM and 
LM were adjusted for HAART use, age, sex, sex and HAART 
interaction, energy intake !35 kcal/kg, and strength training. 
Separate models assessing the effect of CD4+ cell count and 
viral load on BMC were also adjusted for calcium intake less 
than the dietary reference index value, vitamin D intake less 
than the dietary reference index value, and smoking. Interac­
tions of CD4+ cell count and viral load with sex were tested. 
In separate multivariate, longitudinal models, we assessed 
the effect of antiviral medications on body composition ad­
justed for age, sex, baseline value and change in CD4+ cell count, 
baseline value and change in viral load, energy intake !35 kcal/ 
kg, calcium intake less than the dietary reference index value, 
vitamin D intake less than the dietary reference index value, 
strength training, and smoking, as appropriate. Interactions of 
medications with sex were tested. 
RESULTS 
Subjects. One hundred ten men and 42 women (a total of 
152 subject) with a total of 194 intervals met inclusion criteria 
for this analysis. Seventy-six percent of individuals provided 1 
interval for analysis, 20% provided 2 intervals, and 4% provided 
3 intervals. Table 1 presents the baseline assessments for the 
participants. In subjects using HAART at baseline, the median 
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Table 1. Demographic and clinical characteristics of 152 HIV-infected adults enrolled in a longitudinal 
study of body composition alterations at baseline visit for the ﬁrst study interval. 
Variable All subjects Men Women 
No. (%) of subjects 152 (100) 110 (72) 42 (28) 
Age, mean years  SD 42.7  6.9 43.5  6.8a 40.7  6.8 
Body mass index, mean  SD 24.9  4.2 24.4  3.8b 26.4  4.8 
Time since diagnosis, mean years  SD 7.4  3.6 7.4  3.6 7.3  3.7 
Baseline CD4+ cell count, mean cells/mm3  SD 430  227 398  224b 522  211 
Annualized D in CD4+ cell count, mean cells/mm3  SD �1  125 4  115 �15  152 
Viral load, median log10 copies/mL (IQR) 2.3 (2.3–3.8) 2.3 (2.3–3.9) 2.3 (2.3–3.1) 
Annualized D in viral load, median log10 copies/mL (IQR) 0 (�0.08 to 0.07) 0 (�0.08 to 0.09) 0 (0.0–0.0) 
AIDS diagnosis, no. (%) of subjects 82 (54.0) 62 (56.4) 20 (47.6) 
Nonwhite ethnicity, no. (%) of subjects 54 (35.5) 32 (29.1)b 22 (52.4) 
Men who have sex with men, no. (%) of subjects 91 (59.9) 91 (82.7) NA 
History of injection drug use, no. (%) of subjects 15 (9.9) 8 (7.3) 7 (16.7) 
Strength training in past week, no. (%) of subjects 37 (24.5) 34 (30.9)b 3 (7.3) 
Current smoker, no. (%) of subjects 60 (40.0) 34 (31.2)b 26 (63.4) 
NOTE. Student’s t test, x2 test, Wilcoxon rank sum test, or Fisher exact test were used as appropriate. IQR, interquartile 
range. 
a Statistically signiﬁcant difference between men and women ( P ! .05).
 

b Statistically signiﬁcant difference between men and women ( P � .01).
 

time of continuous HAART use prior to the initial assessment intake (i.e., !35 kcal/kg of body weight) (69.1% of women vs. 
visit was 15.3 months (interquartile range, 7.0–26.7 months). 30.9% of men; P ! .001 ) (data not shown). There were no sta-
Median interval length was 12.9 months (interquartile range, tistically signiﬁcant differences by sex, except that women were 
12.1–17.6 months). Of the 165 HAART-use intervals, 89.7% of less likely to use HAART (76.2% vs. 90.9%; P p .02), more 
these involved regimens that were PI-based HAART; 29 were likely to use non-HAART antiretroviral therapies (23.8% vs. 
non-HAART intervals. 8.2%; P p .009) (data not shown), and had been receiving 
Table 1 shows differences between men and women in the HAART for a shorter duration (median duration, 6.8 vs. 15.2 
cohort. On the basis of 3-day food record from their initial months; P p .02) than were men. Baseline regional body com­
visit, women were more likely to report insufﬁcient calcium position differed by sex (table 2); women had nearly double 
intake (69.1% did not meet the dietary reference index value, the FM, two-thirds the LM, and less BMC than men (P !
compared with 34.6% of men; P ! .001 ) and insufﬁcient energy .001 for all). No differences in annualized percentage change 
Table 2. Baseline values and changes in regional body composition as assessed by dual-energy x-ray absorptiometry after the ﬁrst 
study interval for 152 HIV-infected adults enrolled in a longitudinal study of body composition alterations. 
Unadjusted baseline value, Unadjusted annualized percentage 
median kg (IQR) change, mean %  SD 
All subjects Men Women All Men Women 
(n p 152) (n p 110) (n p 42) (n p 152) (n p 110) (n p 42) 
Fat mass 
Extremitiesa 6.7 (4.1–10.4) 5.3 (3.8–7.6)b 11.8 (8.7–16.3) �3.9  20.0 �5.3  19.0 �0.31  22.4 
Trunk 8.2 (4.6–11.6) 6.8 (3.9–10.1)b 11.2 (8.0–16.7) 4.4  35.1 4.1  30.9 5.2  44.8 
Lean body mass 
Extremitiesa 22.9 (18.8–26.4) 24.8 (22.0–27.5)b 16.0 (14.5–18.6) 0.33  5.6 �0.32  4.8 2.0  7.0 
Trunk 27.2 (23.5–30.8) 29.3 (26.5–32.0)b 21.0 (19.3–23.5) 0.96  4.1 0.65  4.0 1.8  4.2 
Bone mineral content 
Extremitiesa 1.3 (1.1–1.5) 1.4 (1.3–1.5)b 1.1 (1.0–1.2) �0.71  4.03 �0.67  4.2 �0.82  3.7 
Trunk 0.65 (0.57–0.73) 0.67 (0.58–0.75)b 0.57 (0.51–0.61) �0.05  5.4 0.78  5.0c �2.3  5.9 
NOTE. Student’s t test, x2 test, Wilcoxon rank sum test, or Fisher exact test were used as appropriate. IQR, interquartile range. 
a Determined by the sum of arms plus legs to as deﬁned by dual-energy x-ray absorptiometry scan. 
b Statistically signiﬁcant difference between men and women ( P ! .001). 
Statistically signiﬁcant difference between men and women ( P p .003). 
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Figure 2. Effects of baseline value and change in CD4+ cell count and 
viral load on fat mass, as assessed by dual-energy x-ray absorptiometry. 
Data are expressed as the estimate of coefﬁcient (SE) for annualized 
percentage change in fat mass from the beginning of an interval, adjusted 
for a theoretical 1-year period, per 100 cells/mm3 and per log10 copies/ 
mL, respectively. Effects of baseline CD4+ cell count on extremity fat 
mass are shown as separate bars for men and women because of sta­
tistically signiﬁcant interaction; in men, the association is statistically 
signiﬁcant ( P p .005). Separate models were run for the 4 predictors of 
interest: baseline CD4+ cell count, change in CD4+ cell count, baseline 
viral load, and change in viral load. Each model was adjusted for HAART, 
age, sex, and the combination of sex and HAART. In addition, the model 
was adjusted for caloric intake !35 g/kg. The interaction between sex 
and the predictor of interest was tested for each model. For extremity 
fat mass, the interaction of sex and baseline CD4+ cell count was sta­
tistically signiﬁcant ( P p .04). Bars, standard error. * P ! .05. 
in regional body composition were observed between men and 
women, except for trunk BMC ( P p .003) (table 2). 
Predictors of Regional Body Composition Changes 
Examining all 194 intervals (unadjusted interval data not 
shown), the cohort experienced an average annual loss of 3.6% 
of extremity FM ( P p .011 ), with greater changes seen in men. 
Increases in trunk FM were not signiﬁcant ( P p .66). Trunk 
LM (nonfat, nonbone mass) increased 0.9% per year (P p
.002), whereas extremity LM did not change. Small decreases 
in extremity BMC were not statistically signiﬁcant. Women had 
a statistically signiﬁcant annual loss of trunk BMC (mean un­
adjusted change [SD] in women, �1.5%  5.6%; mean 
unadjusted change [SD] in men, 0.94%  5.0%; P p .004 
for sex interaction). 
Baseline CD4+ cell count. Figures 2–4 illustrate adjusted 
models examining CD4+ cell count and viral load effects on 
regional changes. A positive linear relationship existed between 
change in trunk fat and baseline CD4+ cell count, with a 2.3% 
annualized mean increase in trunk fat per 100 CD4+ cells/mm3 
(95% CI, 0.7%–3.9%; P p .006). The relationship between ex­
tremity FM and baseline CD4+ cell count varied by sex (P p
.02 for sex interaction). Baseline CD4+ cell count predicted a 
1.8% annualized mean increase in extremity FM per 100 CD4+ 
cells/mm3 in men only (95% CI, 0.6%–3.0%; P p .005); for 
women, the association was not statistically signiﬁcant (P p
.18 ). Baseline CD4+ cell count was not associated with changes 
in LM or BMC. 
Change in CD4+ cell count. Extremity LM increased with 
changes in CD4+ cell count from baseline (mean increase per 
year, 0.59% per 100 cells/mm3; 95% CI, 0.05%–1.1%; P p
.03). 
Baseline viral load. Higher viral load at baseline predicted 
a subsequent loss of extremity FM (mean decrease per year, 
�3.4% per log10 copies/mL; 95% CI, �6.1% to �0.6%; P p
.02) and trunk FM (mean decrease per year, �5.0% per log10 
copies/mL; 95% CI, �9.4% to �0.7%; P p .03). 
Change in viral load. No association was found between 
change in viral load and regional body composition changes. 
Use of HAART or antiretroviral therapy. Table 3 shows 
the association between use of speciﬁc antiretroviral therapy 
and HAART regimens and body composition changes in ad­
justed models. HAART use (found in 146 intervals) was as­
sociated with a mean annual 1.6% loss of extremity BMC in 
both sexes (95% CI, �3.1% to �0.08%; P p .04) and a mean 
2.5% annualized LM increase in women (95% CI, 0.5%–4.6%; 
P p .02) but with no other body composition changes. 
Increased extremity LM (mean increase per year, 2.8%; 95% 
CI, 0.1%–5.6%; P p .04) was associated with NNRTI-based 
HAART regimens, but the number of intervals analyzed was 
very small (16 of 169 intervals analyzed involved NNRTI-based 
HAART regimens). PI-based HAART (used in 92 of 169 in­
tervals) was associated with extremity BMC loss (mean decrease 
per year, �1.9%; 95% CI, �3.6% to �0.2%; P p .03), but no 
other HAART regimen had this association. 
Zidovudine use (found in 60 of 103 intervals analyzed) was 
associated with an annual decrease in extremity FM (mean 
decrease per year, �4.9%; 95% CI, �9.8% to �0.01%; P p
.049) and trunk FM (mean decrease per year, �10.8%; 95% 
CI, �20.4% to �1.4%; P p .02). Zalcitabine use was associated 
with a decrease in trunk FM, and stavudine use was not. Use 
of lamivudine (found in 117 of 127 intervals) was associated 
with increased trunk LM (mean increase per year, 3.0%; 95% 
CI, 0.1%–5.8%; P p .04). Although few individuals were re­
ceiving didanosine (found in 27 of 137 intervals), use of the 
agent was associated with a decrease in trunk LM (mean de­
crease per year, �6.4%; 95% CI, �10.3% to �2.5%; P p
.002) in women only. Zidovudine use (found in 60 of 103 
intervals) was associated with an annual decrease in trunk BMC 
(mean decrease per year, �2.6%; 95% CI, �4.4% to �0.8%; 
P p .005). The use of stavudine (found in 69 of 130 intervals) 
was associated with an increase in trunk BMC (mean increase 
per year, 2.0%; 95% CI, 0.4%–3.6%; P p .01 ). 
Adjusted models found no effect on regional FM attributable 
to use of any individual PI (table 3), but saquinavir use (found 
in 28 of 91 intervals) and ritonavir use (found in 24 of 92 






























o Baseline CD4" cell count
• Change in CD4- cell count
o Baseline viral load




















o Baseline CD4+ cell count
• Change in CD4+ cell count
o Baseline viral load
• Change in viral load
Figure 3. Effects of baseline value and change in CD4+ cell count and viral load on lean mass, as assessed by dual-energy x-ray absorptiometry. 
Data are expressed as the estimate of coefﬁcient (SE) for annualized percentage change in lean mass from the beginning of an interval, adjusted 
for a theoretical 1-year period, per 100 cells/mm3 and per log10 copies/mL, respectively. Separate models were run for the 4 predictors of interest: 
baseline CD4+ cell count, change in CD4+ cell count, baseline viral load, and change in viral load. Each model was adjusted for HAART, age, sex, and 
the combination of sex and HAART. In addition, the model was adjusted for caloric intake !35 g/kg. The interaction between sex and the predictor 
of interest was tested for each model. Bars, standard error. * P ! .05. 
intervals) were each associated an annualized decrease in ex- Low energy intake predicted a large loss of trunk fat (co­
tremity LM (mean decrease per year, �1.4% [95% CI, �2.7% efﬁcient range, �7.8% to �17.1% per year; P ! .05 for all) in 
to �0.7%] and �1.8% [95% CI, �3.2% to �0.4%], respec- models examining the effect of viral load change, HAART use, 
tively; P p .04 and P p .01 , respectively). Nelﬁnavir use (found and the PIs ritonavir, indinavir, nelﬁnavir, and saquinavir and 
in 43 of 98 intervals) was associated with a 2.2% annualized was retained in these models. Cigarette smoking was associated 
increase in extremity BMC (95% CI, 1.2%–3.2%; P ! .001 ). with annual decreases in BMC in the trunk (coefﬁcient range, 
Figure 4. Effects of baseline value and change in CD4+ cell count and viral load on bone mineral content, as assessed by dual-energy x-ray 
absorptiometry. Data are expressed as the estimate of coefﬁcient (SE) for annualized percentage change in bone mineral content from the beginning 
of an interval, adjusted for a theoretical 1-year period, per 100 cells/mm3 and per log10 copies/mL, respectively. Separate models were run for the 4 
predictors of interest: baseline CD4+ cell count, change in CD4+ cell count, baseline viral load, and change in viral load. Each model was adjusted for 
HAART, age, sex, and the combination of sex and HAART. In addition, the model was adjusted for smoking status, vitamin D intake less than the 
dietary reference intake value, and calcium intake less than the dietary reference intake value. The interaction between sex and the predictor of 
interest was tested for each model. For the covariate of smoking status, there was a statistically signiﬁcant association with change in extremity 
bone mineral content ( P ! .001 for all) and trunk bone mineral content ( P � .03). Bars, standard error. * P ! .05. 
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Table 3. Effect of antiretroviral therapy on annualized percentage change in regional body composition of HIV-infected adults receiving stable medication regimens. 
Intervals with Annualized percentage change in regional body composition to estimate of coefﬁcient (95% CI)a 
Total no. continuous 
of intervals regimen use Extremity Trunk 
in the to no. (%) of Extremity Trunk Extremity Trunk bone mineral bone mineral 
Comparison group to by class analysis total intervals fat mass fat mass lean body mass lean body mass content content 
By type of regimen 
HAART vs. HAART naive 170 146 (85.9) �2.2 (�8.8 to 4.3) 2.3 (�5.0 to 9.6) 0.03 (�1.8 to 1.9) Men: �0.98 (�2.0 to 0.2); �1.6 (�3.1 to �0.08)b �0.10 (�1.9 to 1.7) 
women: 2.5 (0.5–4.6)b 
PI-based HAART vs. HAART naive 169 92 (54.4) �2.0 (�9.5 to 5.4) 6.0 (�2.8 to 14.8) 0.30 (�1.7 to 2.3) 0.83 (�0.6 to 2.3) �1.9 (�3.6 to �0.2)b �0.09 (�2.1 to 1.9) 
Mixed HAART vs. HAART naive 169 37 (21.9) �1.4 (�8.8 to 6.0) 3.9 (�4.8 to 12.6) �1.5 (�3.7 to 0.7) �0.78 (�2.2 to 0.7) �1.4 (�3.2 to 0.4) 0.78 (�1.2 to 2.8) 
NNRTI-based HAART vs. HAART naive 169 16 (9.5) �5.4 (�15.1 to 4.2) 3.1 (�8.0 to 14.3) 2.8 (0.1–5.6)b 1.2 (�0.6 to 3.1) �0.70 (�2.7 to 1.3) �1.6 (�4.5 to 1.2) 
By drug 
Speciﬁc PI-based HAART vs. all other 
PI-based HAART naive 
Nelﬁnavir 98 43 (43.9) �2.7 (�9.5 to 4.1) 0.87 (�7.5 to 9.3) 0.89 (�0.8 to 2.5) 0.56 (�0.8 to 1.9) 2.2 (1.2–3.2)c 0.02 (�1.7 to 1.7) 
Indinavir 87 31 (35.6) 6.1 (�1.1 to 13.3) 4.9 (�4.1 to 13.8) 0.08 (�1.6 to 1.8) �0.41 (�1.8 to 1.0) �0.06 (�1.2 to 1.1) 0.26 (�1.8 to 2.4) 
Saquinavir 91 28 (30.8) �0.75 (�8.0 to 6.5) �5.3 (�14.0 to 3.4) �1.4 (�2.7 to �0.7)b 0.36 (�1.1 to 1.8) �1.3 (�3.0 to 0.4) 0.43 (�1.6 to 2.4) 
Ritonavir 92 24 (26.1) �0.26 (�8.3 to 7.8) �7.9 (�18.8 to 3.1) �1.8 (�3.2 to �0.4)b �0.26 (�1.5 to 1.0) �1.6 (�3.4 to 0.1) �0.67 (�3.0 to 1.6) 
Speciﬁc NRTI-based HAART vs. all 
other NRTI HAART 
Lamivudine 127 117 (92.1) �9.3 (�24.2 to 5.7) �18.5 (�41.5 to 4.4) 1.8 (�0.13 to 3.7) 3.0 (0.10–5.8)b �0.67 (�3.5 to 2.2) �0.92 (�4.7 to 2.8) 
Zidovudine 103 60 (58.3) �4.9 (�9.8 to �0.01)b �10.8 (�20.1 to �1.4)b 0.66 (�1.02 to 2.3) 0.88 (�0.39 to 2.1) �1.2 (�2.4 to 0.10) �2.6 (�4.4 to �0.8)c 
Stavudine 130 69 (53.1) �0.11 (�5.8 to 5.6) 2.9 (�6.1 to 11.9) 0.12 (�1.4 to 1.6) �0.17 (�1.3 to 1.0) �0.39 (�1.4 to 0.62) 2.0 (0.42– 3.6)b 
Didanosine 137 27 (19.7) 0.70 (�8.5 to 9.9) �3.6 (�17.1 to 9.9) 0.08 (�1.8 to 2.0) Men: 0.66 (�0.94 to 2.3); �0.26 (�1.9 to 1.4) 0.54 (�1.5 to 2.6) 
women: �6.4 (�10.3 to �2.5)c 
Zalcitabine 141 6 (4.3) �4.8 (�11.8 to 2.3) �14.1 (�25.7 to �2.6)b �1.3 (�3.1 to 0.5) Men: 0.70 (�0.34 to 1.7); �1.0 (�2.7 to 0.7) 0.90 (�3.0 to 4.8) 
women: �3.4 (�6.8 to �0.03)b 
NOTE. This table summarizes many adjusted models. Sample sizes vary from model to model, because each analysis includes only subject ﬁles that have complete covariate data and meet all inclusion criteria. A subject 
was considered to be in the ART group or HAART group if they reported continuous ART or HAART use from the beginning of the interval through the end of the interval. A subject was considered to be ART or HAART 
naive if the subject reported no ART or HAART use in the 12 months prior to entry into the Nutrition for Healthy Living Study and did not receive ART or HAART through the end of the interval. PI-based HAART was deﬁned 
as �2 PIs or 1 PI and 2 NRTIs. Mixed HAART was deﬁned as �1 NRTI, 1 PI, and 1 NNRTI. NNRTI-based HAART was deﬁned as �1 NNRTI and 2 PIs. 3-NRTI HAART was deﬁned as �3 NNRTIs. ART, antiretroviral therapy; 
NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor. 
a Models were adjusted for sex, age, CD4+ cell count baseline value, change in CD4+ cell count, viral load baseline value, change in viral load, energy intake !35 g/kg, and strength training. Bone mineral content models 
were also adjusted for smoking, calcium intake less than the dietary reference intake value, and vitamin D intake less than the dietary reference intake value. Drug/sex interactions were tested for all drugs. 
b P �  .05 by Student’s t test, x  2 test, Fisher’s exact test, or Wilcoxon rank sum test, as appropriate. 




�1.4% to �2.3%) and extremities (coefﬁcient range, �1.1% 
to �3.2%). In the HAART model, each year of age predicted 
a more rapid decrease in trunk LM (mean decrease per year, 
�0.05%; 95% CI, �0.09% to �0.006%; P p .03). 
DISCUSSION 
With the advent of new and effective antiretroviral therapies, 
immune restoration and viral suppression are now possible in 
HIV-infected adults in the United States. As a result, it has been 
difﬁcult to determine which medication and host factors are 
associated with the varying aspects of body composition alter­
ations. Many previously reported analyses did not use contin­
uous or objective measures of change, have been cross-
sectional, have not included HAART-naive persons for 
comparison, did not look directly at the effects of CD4+ cell 
counts or viral loads after adjustment, or did not consider such 
behaviors as dietary intake and smoking [6, 7, 14, 22]. Although 
case reports and initiation studies have implicated the intro­
duction of HAART in rapidly inducing body-shape changes in 
some people, it remains unclear whether these changes continue 
to evolve with continuous HAART or antiretroviral therapy 
use. We offer exploratory ﬁndings from a longitudinal exam­
ination of regional body composition changes in a large cohort 
of HAART or antiretroviral therapy–experienced and –naive 
men and women, and we demonstrate ongoing changes in 
individuals receiving stable therapies. 
This analysis conﬁrms an average annual loss of extremity 
fat in the cohort. DEXA cannot distinguish between upper and 
lower trunk fat, nor can it distinguish between the visceral and 
subcutaneous compartments of the abdomen, but total trunk 
fat changes were not found. Most importantly, disease status 
was associated with regional body changes, because a lower 
baseline CD4+ cell count ( P � .006) or a higher baseline viral 
load ( P � .03) predicted a greater loss of trunk and limb fat. 
HAART use or its duration did not contribute to change. Of 
interest, zidovudine but not stavudine was associated with loss 
of limb and trunk fat. Because of the time frame in which data 
were collected, we were unable to determine the effect of some 
individual medications, including abacavir and the NNRTIs. 
These ﬁndings agree with the current literature that suggests 
lipoatrophy is the unique physical manifestation of HIV infec­
tion, and they support the ﬁndings from our group and others 
that disease status is involved [4, 6, 19, 23–25]. However, it 
remains impossible to separate the individual effects of anti­
retroviral therapy agents, because they are used in combination. 
Changes in LM have been less well investigated in the 
HAART era. An early report from our group found that, after 
HAART initiation, weight increased, and LM did not [8], but 
our later reports found greater LM in individuals receiving 
HAART than in others [5]. The current longitudinal study 
conﬁrms that ongoing improvement in CD4+ cell count was 
concurrent with gains in extremity LM, perhaps because the 
latter reﬂects improved health, nutrition, and mobility that may 
occur with an improvement in CD4+ cell count. 
It appears that both medication and modiﬁable lifestyle fac­
tors altered bone health in our cohort. HAART use and PI use 
remained associated with bone mineral loss, even after adjust­
ment for the strong effects of numerous well-known osteopenia 
cofactors. Other signiﬁcant risk factors included cigarette smok­
ing and dietary practices. The literature has been conﬂicted 
about the prevalence of predictors of BMC changes [12, 26– 
29]. Our analysis supports the involvement of antiretroviral 
therapy, as well as known risk factors, reinforcing the need for 
additional longitudinal studies that account for diet, cigarette 
smoking, and medications concurrently. 
Although a cohort such as this does not allow us to examine 
the changes induced by the introduction of HAART (as would 
be possible in a randomized control trial), our data do assist 
in understanding the real-world situation for many patients 
who experience ongoing body changes over time while receiving 
treatment. Though our numbers were small for some analyses, 
statistical differences were apparent. These ﬁndings suggest the 
importance of peak viral load and nadir CD4+ cell count on 
the subsequent loss of fat, a concurrence in the improvements 
in CD4+ cell count and LM, and the primary inﬂuences of 
medications and traditional risk factors in bone deminerali­
zation. Many details about HIV-associated body composition 
alterations remain unanswered, but this work conﬁrms the 
growing body of evidence that such changes are multifactorial. 
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